Peptide conjugates of therapeutically used antitubercular isoniazid—design, synthesis and antimycobacterial effect

Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis, a slow‐growing, powerful human pathogen which can survive in the host macrophages. In the chemotherapy of such intracellular pathogens it is necessary to achieve relatively high level of the drug in blood to attain therapeutically effective concentration in infected cells, which presumably has several serious side effects on healthy tissues. The elimination of M. tuberculosis from infected phagocytes could be more efficient with target cell‐directed delivery of antituberculars. A particularly promising approach is to conjugate a drug moiety to a peptide based carrier. The conjugates are chemically constructed to target release by hydrolysis (enzymatic and/or chemical) to liberate the active compound. Here we report the synthesis, characterisation and antimycobacterial evaluation of isoniazid (INH) peptide conjugates. As carrier moiety T‐cell epitope of immundominant 16‐kDa protein of M. tuberculosis and tuftsin‐derived peptides were used. To conjugate INH two synthetic methods were developed, where INH was coupled directly to the peptides or through a heterobifunctional reagent. We found that all of the INH conjugates were effective against M. tuberculosis and the minimal inhibitory concentration (MIC) values were comparable to the free INH moiety. Copyright © 2009 European Peptide Society and John Wiley & Sons, Ltd.

[1]  S. Gordon,et al.  The mannose receptor: linking homeostasis and immunity through sugar recognition. , 2005, Trends in immunology.

[2]  T. Sundaresan,et al.  WHO CO-OPERATIVE STUDIES ON A SIMPLE CULTURE TECHNIQUE FOR THE ISOLATION OF MYCOBACTERIA. 2. COMPARISON OF THE EFFICACY OF LYOPHILIZED LIQUID MEDIUM WITH THAT OF LOEWENSTEIN-JENSEN (L-J) MEDIUM. , 1963, Bulletin of the World Health Organization.

[3]  K. Brown,et al.  Oxidation of isoniazid by manganese and Mycobacterium tuberculosis catalase-peroxidase yields a new mechanism of activation. , 2001, Journal of the American Chemical Society.

[4]  K. Geoghegan,et al.  Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. , 1992, Bioconjugate chemistry.

[5]  J. Yates,et al.  Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants. , 1994, Journal of immunology.

[6]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[7]  John I. Clark,et al.  Functional similarities between the small heat shock proteins Mycobacterium tuberculosis HSP 16.3 and human alphaB-crystallin. , 2002, European journal of biochemistry.

[8]  R. M. Simpson,et al.  The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Krieger,et al.  Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). , 1994, Annual review of biochemistry.

[10]  G. Babcock,et al.  Receptor‐mediated Internalization of Tuftsin a , 1983, Annals of the New York Academy of Sciences.

[11]  S. Basu,et al.  Killing of intracellular Mycobacterium tuberculosis by receptor-mediated drug delivery , 1991, Antimicrobial Agents and Chemotherapy.

[12]  C. Watts.  The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules , 2004, Nature Immunology.

[13]  M. Przybylski,et al.  Design, structural, and immuno‐analytical properties of antigenic bioconjugates comprising a β‐amyloid‐plaque specific epitope , 2008, Biopolymers.

[14]  C. Watts,et al.  Capture and processing of exogenous antigens for presentation on MHC molecules. , 1997, Annual review of immunology.

[15]  K. Cermakova,et al.  Synthesis and antimicrobial evaluation of new 2-substituted 5,7-di-tert-butylbenzoxazoles. , 2006, Bioorganic & medicinal chemistry.

[16]  S T Cole,et al.  Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis , 1993, Journal of bacteriology.

[17]  V. Najjar,et al.  The chemical synthesis of the phagocytosis-stimulating tetrapeptide tuftsin (Thr-Lys-Pro-Arg) and its biological properties. , 1973, Biochimica et biophysica acta.

[18]  L. Köhidai,et al.  Design, synthesis, and in vitro activity of novel drug delivery systems containing tuftsin derivatives and methotrexate. , 2008, Bioconjugate chemistry.

[19]  A. Lanzavecchia,et al.  Peptide partners call the tune , 1994, Nature.

[20]  S Gordon,et al.  Macrophage receptors and immune recognition. , 2005, Annual review of immunology.

[21]  R. Wilkinson,et al.  Enhancement of the T cell response to a mycobacterial peptide by conjugation to synthetic branched polypeptide , 1999, European journal of immunology.

[22]  Matthew W. Anderson,et al.  HLA-DM Mediates Epitope Selection by a “Compare-Exchange” Mechanism when a Potential Peptide Pool Is Available , 2008, PloS one.

[23]  R W Chesnut,et al.  Characterization of the specificity of peptide binding to four DR haplotypes. , 1990, Journal of immunology.

[24]  V. Najjar.  Tuftsin, A Natural Activator of Phagocyte Cells: An Overview a , 1983, Annals of the New York Academy of Sciences.

[25]  J. Reményi,et al.  Synthesis, conformation, and immunoreactivity of new carrier molecules based on repeated tuftsin‐like sequence , 2004, Biopolymers.

[26]  K. Rose,et al.  Construction of protein analogues by site-specific condensation of unprotected fragments. , 1992, Bioconjugate chemistry.

[27]  E. Kaiser,et al.  Color test for terminal prolyl residues in the solid-phase synthesis of peptides , 1980 .

[28]  Y. Zhang,et al.  Molecular genetics of drug resistance in Mycobacterium tuberculosis. , 1994, The Journal of antimicrobial chemotherapy.

[29]  D. Crane,et al.  Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog , 1996, Journal of bacteriology.

[30]  I. Siemion,et al.  Tuftsin: On the 30-year anniversary of Victor Najjar’s discovery , 1999, Peptides.

[31]  W. Mitchell,et al.  Characteristics and isolation of the phagocytosis-stimulating peptide, tuftsin. , 1973, Biochimica et Biophysica Acta.

[32]  C. E. Barry,et al.  The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis. , 2000, Microbes and infection.

[33]  M. Noble,et al.  Binding of the anti‐tubercular drug isoniazid to the arylamine N‐acetyltransferase protein from Mycobacterium smegmatis , 2005, Protein science : a publication of the Protein Society.

[34]  G. Schoolnik,et al.  Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. , 2006, Microbes and infection.

[35]  R. Slayden,et al.  Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis , 2000, Molecular microbiology.

[36]  P. Satoh,et al.  The characteristics, isolation and synthesis of the phagocytosis stimulating peptide tuftsin. , 1972, Biochemical and biophysical research communications.

[37]  L. Šula.  WHO CO-OPERATIVE STUDIES ON A SIMPLE CULTURE TECHNIQUE FOR THE ISOLATION OF MYCOBACTERIA. 1. PREPARATION, LYOPHILIZATION AND RECONSTITUTION OF A SIMPLE SEMI-SYNTHETIC CONCENTRATED LIQUID MEDIUM; CULTURE TECHNIQUE; GROWTH PATTERN OF DIFFERENT MYCOBACTERIA. , 1963, Bulletin of the World Health Organization.